Database and Biobank of Patients With Hypersensitivity Pneumonitis
- Conditions
- Hypersensitivity Pneumonitis
- Registration Number
- NCT05549635
- Lead Sponsor
- Nils Hoyer
- Brief Summary
Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data.
The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016.
Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
- Diagnosis of HP at an MDT conference according to the current international guidelines
- Age of 18 years or older
- The patients must be capable of giving informed consent
- Unable to sign informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival 3 years Survival after diagnosis
Diagnosis of HP 0 days MDT-Diagnosis of HP
Exposure to inciting antigen (patient reported) 0 days Known exposure, as reported by the patient
Exposure to inciting antigen (measurable) 0 days Measurable exposure, as tested by precipitins
Progression free survival 3 years Survival without progression
- Secondary Outcome Measures
Name Time Method Pulmonary function test 3 years DLCO
Imaging 3 years HRCT scans
Quality of life questionnaires 3 years SGRQ
Trial Locations
- Locations (1)
Department of respiratory medicine
🇩🇰Hellerup, Copenhagen, Denmark